Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corp (ICU) is a pioneering medical technology company dedicated to mitigating the life-threatening consequences of hyperinflammation on vital organs. Operating within the healthcare and therapeutic technology industry, the company develops innovative extracorporeal therapies designed to address systemic inflammation by targeting effector cells, which are central to immune response dysregulation. These effector cells can cause direct tissue damage and release pro-inflammatory cytokines that exacerbate immune imbalances, leading to severe complications such as organ failure.
Core Business and Technology
At the heart of SeaStar Medical's operations is its proprietary technology aimed at reducing hyperinflammation. The company's extracorporeal therapies are engineered to selectively target and modulate effector cells, thereby interrupting the cycle of inflammation that can lead to organ damage. This approach represents a significant advancement in the treatment of conditions where systemic inflammation plays a critical role, such as acute kidney injury, sepsis, and other severe inflammatory disorders. By focusing on the root cause of immune dysregulation rather than merely addressing symptoms, SeaStar Medical offers a novel solution with the potential to improve patient outcomes and reduce healthcare costs.
Business Model and Revenue Generation
SeaStar Medical's business model centers on the development and commercialization of its proprietary therapies. Revenue streams likely include direct sales of its medical devices to healthcare providers, licensing agreements with pharmaceutical or biotechnology companies, and potential partnerships for co-development or distribution. The company’s focus on extracorporeal therapies positions it as a key player in a specialized market segment, where demand for innovative solutions to manage systemic inflammation is growing.
Market Context and Competitive Landscape
SeaStar Medical operates within the broader medical technology and therapeutic solutions industry, a sector characterized by rapid innovation and stringent regulatory requirements. The company’s focus on hyperinflammation addresses a critical unmet need in healthcare, particularly in the management of acute and chronic conditions that involve immune system dysregulation. Competitors in this space may include other firms specializing in extracorporeal therapies, immunomodulation technologies, or inflammation-targeting pharmaceuticals. However, SeaStar Medical differentiates itself through its proprietary focus on effector cells, offering a targeted approach that sets it apart from more generalized treatments.
Challenges and Opportunities
Like many companies in the medical technology sector, SeaStar Medical faces challenges such as navigating complex regulatory pathways, securing clinical validation for its therapies, and competing against well-established players. However, the company’s unique approach to targeting effector cells provides a competitive edge, particularly if clinical outcomes demonstrate significant efficacy and safety advantages. Additionally, the growing recognition of hyperinflammation as a critical factor in various medical conditions presents a substantial market opportunity for the company’s solutions.
Significance in the Healthcare Industry
SeaStar Medical’s innovative therapies have the potential to transform the management of systemic inflammation, offering new hope for patients suffering from conditions with limited treatment options. By addressing the underlying mechanisms of immune dysregulation, the company contributes to a paradigm shift in how inflammatory diseases are treated, emphasizing precision and targeted intervention. This positions SeaStar Medical as a significant player in the advancement of medical technology and therapeutic solutions.
SeaStar Medical Holding (Nasdaq: ICU) announces that its NEUTRALIZE-AKI pivotal trial has enrolled 51 subjects, surpassing the halfway point towards the 100-subject target for an interim analysis. The trial evaluates the safety and efficacy of SeaStar's Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI) in ICU receiving continuous kidney replacement therapy (CKRT).
Key points:
- Enrollment pace has accelerated since summer, with 5 subjects enrolled in October
- SCD received FDA Breakthrough Device Designation for adults with AKI
- Centers for Medicare & Medicaid Services granted Category B coverage for certain expenses in July 2024
- SeaStar began shipping SCD Pediatric (QUELIMMUNE™) in July 2024
- The company extinguished all interest-bearing debt in September 2024
The NEUTRALIZE-AKI trial aims to enroll up to 200 adults at up to 30 clinical sites, with a primary endpoint of 90-day mortality or dialysis dependency.
SeaStar Medical Holding (Nasdaq: ICU) announces the presentation of new analyses of clinical data supporting the immunomodulating effect of the Selective Cytopheretic Device (SCD) at the American Society of Nephrology (ASN) 2024 Kidney Week. The data shows how the SCD significantly lowered biomarkers related to inflammation in critically ill patients with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).
A poster presentation will highlight how SCD treatment significantly reduced the Neutrophil: Lymphocyte Ratio (NLR), a powerful biomarker linked to poor outcomes across various diseases. This provides further mechanistic clinical evidence of leukocyte immunomodulation in hyperinflammatory conditions such as AKI and sepsis.
The Company's pediatric SCD, QUELIMMUNE™, was approved by the FDA as a Humanitarian Use Device in February 2024. SeaStar Medical continues to enroll patients in its adult NEUTRALIZE-AKI pivotal trial and advance other indications like cardiorenal syndrome.
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage medical device company, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 16, 2024, at 12:00 p.m. Eastern time. The event, hosted by M-Vest, will feature a discussion with SeaStar Medical's management team, moderated by Maxim Group analyst Anthony Vendetti.
SeaStar Medical specializes in developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. Interested parties can access the live and archived presentation webcast by registering for the M-Vest platform. The webcast link will be available in the Events & Presentations section of the SeaStar Medical website.
SeaStar Medical Holding (Nasdaq: ICU) announces the expansion of its NEUTRALIZE-AKI pivotal trial with the addition of two premier military medical facilities: Brooke Army Medical Center (BAMC) and the United States Army Institute of Surgical Research (USAISR). This brings the total number of active clinical sites to 11, with 48 subjects enrolled to date. The trial is evaluating the safety and efficacy of SeaStar Medical's Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in adult ICU patients receiving continuous kidney replacement therapy (CKRT).
The SCD has received FDA Breakthrough Device Designation for adults with AKI. In July 2024, CMS granted Category B coverage for certain expenses related to the trial. SeaStar Medical also began shipping its pediatric SCD, branded QUELIMMUNE™, in July 2024 following FDA approval. The company paid off all interest-bearing debt in September 2024.
SeaStar Medical Holding (Nasdaq: ICU) reports progress in its pivotal NEUTRALIZE-AKI trial, with four new subjects enrolled in 10 days, bringing total enrollment to 46. The trial evaluates the company's Selective Cytopheretic Device (SCD) for adults with acute kidney injury (AKI) in ICU receiving continuous kidney replacement therapy (CKRT).
Key points:
- Trial aims to enroll up to 200 adults
- Primary endpoint: 90-day mortality or dialysis dependency
- Interim analysis planned at halfway point
- Company plans to expand trial sites to accelerate enrollment
The SCD is designed to reduce hyperinflammation in AKI patients, potentially improving outcomes and reducing healthcare costs. SeaStar Medical's pediatric version, QUELIMMUNE™, received FDA approval in February 2024 for children with AKI and sepsis.
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage medical device company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management will engage in a fireside chat on September 11, 2024, at 9:00 a.m. Eastern time. Investors can access the webcast through the Events and Presentations section of SeaStar Medical's website.
The conference, scheduled for September 9-11, 2024, will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. SeaStar Medical's management team will be available for one-on-one meetings throughout the event. Institutional investors and industry professionals interested in attending can register for either virtual or in-person participation.
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage medical device company, has eliminated all long-term debt, strengthening its financial position. The company, which develops proprietary solutions to reduce hyperinflammation's impact on vital organs, reported over $9 million in convertible notes and long-term interest-bearing debt at the end of 2023. This debt retirement will be reflected in the balance sheet for the quarter ending September 30, 2024. CEO Eric Schlorff stated that SeaStar Medical is now in its strongest financial position since going public nearly two years ago, enhancing its ability to advance its business plan and deliver potentially life-saving solutions to critically ill patients.
SeaStar Medical (Nasdaq: ICU) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Initial commercial sales of QUELIMMUNE™ for pediatric AKI and sepsis patients.
2. Enrollment of 42 subjects at 9 sites in the NEUTRALIZE-AKI pivotal trial for adults.
3. CMS granted Category B coverage for certain trial expenses.
4. Completed a $10 million financing and retired nearly all outstanding debt.
5. Q2 2024 net loss of $3.2 million, or $1.03 per share.
6. Cash balance of approximately $6.9 million as of July 31, 2024.
The company expects U.S. regulatory approval for the SCD in adults with AKI in H1 2026, with commercial launch in H2 2026.
SeaStar Medical Holding (Nasdaq: ICU) has announced the first commercial treatment of a pediatric patient with its FDA-approved QUELIMMUNE™ therapeutic device. This milestone meets the FDA's August 20, 2024 deadline for initiating patient treatments. QUELIMMUNE is designed to treat acute kidney injury (AKI) in pediatric patients weighing 10 kg or more with sepsis or septic conditions requiring kidney replacement therapy (KRT).
Clinical trials have shown promising results, with a 77% survival rate and no dialysis dependency at 60 days for treated children. This is significant given that approximately 4,000 children with AKI require continuous KRT annually in the U.S., with a mortality rate of about 50%. The company aims to improve outcomes and reduce long-term complications for these severely ill children.
SeaStar Medical Holding (Nasdaq: ICU) has received a Category B Coverage Letter from CMS for its NEUTRALIZE-AKI pivotal trial, evaluating the Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). This coverage is expected to accelerate medical site activations and cover a portion of the trial costs. The trial aims to enroll up to 200 adult patients with AKI at up to 30 clinical sites, with 38 patients already enrolled across 10 active centers.
CEO Eric Schlorff anticipates that CMS reimbursement will provide substantial overall cost savings and accelerate patient enrollment. The company plans to conduct an interim analysis after reaching the 90-day primary endpoint in 100 enrolled subjects. SeaStar Medical views the adult AKI market as a multibillion-dollar opportunity, given its population is 50 times larger than pediatric AKI.
FAQ
What is the current stock price of SeaStar Medical Holding (ICU)?
What is the market cap of SeaStar Medical Holding (ICU)?
What does SeaStar Medical Holding Corp specialize in?
How does SeaStar Medical's technology work?
What market does SeaStar Medical operate in?
What challenges does SeaStar Medical face?
What differentiates SeaStar Medical from competitors?
Who are the likely customers of SeaStar Medical?
What conditions can SeaStar Medical's therapies address?
How does SeaStar Medical generate revenue?
